Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 789-798

  Bougeret, Cécile ^a   Virone Oddos, Angela ^a   Adeline, Emmanuelle ^a   Lacroix, Frédéric ^a   Lefranc, Céline ^a   Ferrero, Lucy ^a   Huet, Thierry ^a,b  

^a SANOFI   (France)

^b Aventis Gencell   (United States)

Author keywords

Apoptosis; Cancer gene therapy; Murine double minute 2; P53; Recombinant adenovirus

Indexed keywords

DNA; PROTEIN P53;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER THERAPY; CELL CYCLE; CONTROLLED STUDY; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0034065319     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700163     Document Type: Article

References (46)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
2. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
4. Smith ML, Fornace AJJ. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol. 1995;7: 69-75.
5. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
6. Beaudry GA, Bertelsen AH, Sherman MI. Therapeutic targeting of the p53 tumor suppressor gene. Curr Opin Biotechnol. 1996;7:592-600.
7. Zhang W-W, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5-13.
8. Liu T-J, El-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995;55:3117-3122.
9. Hamada K, Alemany R, Zhang W-W, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56:3047-3054.
10. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-991.
11. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
12. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 into the mutant conformation. Cell. 1991;65:765-774.
13. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-1245.
14. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J. 1993;12:2799-2808.
15. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299.
16. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303.
17. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wild-type p53 activity. EMBO J. 1993;12:461-468.
18. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126-1132.
19. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358: 80-83.
20. Leach FS, Tokino T, Meltzer P, et al. P53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53:2231-2234.
21. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993;53:16-18.
22. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 1994;86:1297-1302.
23. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54:794-799.
24. Würl P, Meye A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 1998;16:1183-1185.
25. Sheikh MS, Shao Z-H, Hussain A, Fontana JA. The p53-binding protein MDM2 is differentially expressed in human breast carcinoma. Cancer Res. 1993;53:3226-3228.
26. Marchetti A, Buttitta F, Girlando S, et al. Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol. 1995;175:31-38.
27. Bueso-Ramos CE, Manshouri T, Haidar MA, et al. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996;37:179-188.
28. Gunther T, Schneider-Stock R, Rys J, Niezabitowski A, Roessner A. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma: a comparative analysis with clinico-pathological factors. J Cancer Res Clin Oncol. 1997;123:388-394.
29. Gorgoulis VG, Rassidakis GZ, Karameris AM, et al. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma. Mod Pathol. 1996;9:544-554.
30. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996;180:129-137.
31. Matsumura T, Yoshihama Y, Kimura T, Shintani S, Alcalde RE. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology. 1996;53:308-312.
32. zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55-F78.
33. Mietz JA, Unger T, Huibregtse JM, Howley PM. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 1992;11:5013-5020.
34. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
35. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol. 1995;69:1851-1859.
36. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 1995;9:41-47.
37. Cromlish JA. Hepatitis B virus-induced hepatocellular carcinoma: possible roles for HBx. Trends Microbiol. 1996; 4:270-274.
38. Conseiller E, Debussche L, Landais D, et al. CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest. 1998; 101:120-127.
39. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA. 1994;91:1998-2002.
40. Crouzet J, Naudin L, Orsini C, et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA. 1997;94:1414-1419.
41. Luna L. Manual of Histological Staining Methods of the Armed Forces Institute of Pathology. New York: McGraw Hill Book Co.; 1968.
42. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
43. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
44. Flaman J-M, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA. 1995;92:3963-3967.
45. 1 arrest and induces apoptosis in human cancer cells. Oncogene. 1997;15:1903-1909.
46. Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 1996;3:121-130.